Clinical Trials Logo

Myeloid Malignancy clinical trials

View clinical trials related to Myeloid Malignancy.

Filter by:

NCT ID: NCT04501120 Recruiting - Myeloid Malignancy Clinical Trials

Study of APG2575 Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

Start date: September 28, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the safety, pharmacokinetic profile of APG-2575 single agent and in combination with HHT/AZA in patients with relapsed/refractory AML and related myeloid malignancies.

NCT ID: NCT04214860 Completed - Myeloid Malignancy Clinical Trials

APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

Start date: December 13, 2019
Phase: Phase 1
Study type: Interventional

This clinical trial is a Phase I, open-label, dose-finding and cohort expansion study to determine the safety and preliminary efficacy of APR-246 in combination with venetoclax and azacitidine in patients with myeloid malignancies.

NCT ID: NCT03855371 Recruiting - Aml Clinical Trials

Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS

PANDA-T0
Start date: January 10, 2018
Phase: Phase 1
Study type: Interventional

TP53 mutation is commonly associated with poor cancer patient prognosis yet no mutant p53 (mp53)-targeting regimen was clinically established. Here the investigators try to evaluate the side effect and treatment potential of DAC+ATO in p53 mutated high-risk AML/MDS patients. About 200 AML/MDS patients will be sequenced for TP53 sequence before recruitment. The investigators estimated about 5 patients, based on the reported p53 mutation frequency in AML/MDS, will be p53-mutated. In the trial, the investigators will selectively recruit the mp53 AML/MDS patients that are predicted to respond to DAC+ATO regimen with highest chance (based on the relevant basic studies). The investigators designate mutant p53-based clinical trials as 'PANDA (P53 AND Arsenic)-Trials'.

NCT ID: NCT03850418 Recruiting - Myeloid Malignancy Clinical Trials

Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

Start date: July 1, 2019
Phase: Phase 2
Study type: Interventional

Previous studies provide a rationale for administration of AZA after allo SCT for decreasing chimerism. The investigators hypothesize that azacitidine can be well tolerated after SCT and help decrease rate of decreasing donor chimerism and hence decrease relapse without increasing GVHD

NCT ID: NCT02958462 Recruiting - Clinical trials for Hematologic Neoplasms

Pre-myeloid Cancer and Bone Marrow Failure Clinic Study

Start date: January 16, 2017
Phase: N/A
Study type: Interventional

This clinical trial tests next generation sequencing (NGS) for the detection of precursor features of pre-myeloid cancers and bone marrow failure syndromes. NGS is a procedure that looks at relevant cancer associated genes and what they do. Finding genetic markers for pre-malignant conditions may help identify patients who are at risk of pre-myeloid cancers and bone marrow failure syndromes and lead to earlier intervention.

NCT ID: NCT01596699 Terminated - Metabolic Disease Clinical Trials

Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation

Start date: May 24, 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out what effects, good and/or bad, the addition of clofarabine, a new chemotherapy agent, to a standard busulfan and fludarabine conditioning treatment has. The study will also look at what causes some people to have high drug levels of these medications in their body compared to other people that may have low drug levels even if they all receive the same dose of medication.